ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer.

• Tác giả: Feilin Cao, Lilin Chen, Zhendong Chen, Yingying Du, Xichun Hu, Yuan Lei, Wei Li, Wei Liu, Ping Lu, Xiuqing Nie, Quchang Ouyang, Sanyuan Sun, Tao Sun, Zhongsheng Tong, Haixia Wang, Jingfen Wang, Leiping Wang, Shusen Wang, Xiaojia Wang, Xinshuai Wang, Ying Wang, Jinsheng Wu, Weimin Xie, Faliang Xu, Min Yan, Aimin Zang, Jian Zhang, Qingyuan Zhang, Ruiwen Zhang, Yongqiang Zhang
• Ngôn ngữ: eng
• Ký hiệu phân loại: 523.76 Solar interior
• Thông tin xuất bản: England : Signal transduction and targeted therapy , 2025
• Bộ sưu tập: NCBI
• ID: 167258

Tóm tắt

 This phase III trial aimed to compare ARX788, a site-specific, construct-homogeneous antibody-drug conjugate, with lapatinib plus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC) who had progressed on one line of trastuzumab based regimen. Eligible patients were randomized (1:1) to receive ARX788 (1.5 mg/kg, IV, Q3W) or lapatinib plus capecitabine (LC: lapatinib 1250 mg QD
  capecitabine 1000 mg/m